NOVN

Novan, Inc. Common Stock
NOVN

Delisted

NOVN was delisted on the 25th of July, 2023.

Back to rankings
 

About: Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 (berdazimer gel) as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.

Employees: 90

Healthcare Drug Manufacturers - General

Financial journalist opinion

Positive
Barrons
1 month ago
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
Positive
Invezz
3 months ago
Novartis has cash for a big pharma deal—but here's why it's not buying
Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it's just not interested in one, according to its chief executive Vasant Narasimhan. That's because the bigger deals have historically not paid off in the pharmaceutical sector.
Novartis has cash for a big pharma deal—but here's why it's not buying
Positive
Invezz
8 months ago
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different path. While competitors like Eli Lilly and Novo Nordisk race to capture the booming weight-loss drug market, Novartis is steering clear of the frenzy.
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
See News Rankings
Charts implemented using Lightweight Charts™